Abstracts tagged "rheumatoid arthritis (RA) and thyroid"

Abstract Number: 539 • 2018 ACR/ARHP Annual Meeting
Thyroid Function in Early Versus Established Rheumatoid Arthritis
Suad Hannawi¹, Issa Al Salmi² and Haifa Hannawi³, ¹Rheumatology Department. Ministry of Health and Prevention, Asst.Prof, Dubai, United Arab Emirates, ²Prof, Muscat, Oman, ³Research Department. Ministry of Health and Prevention, Asst.Prof, Dubai, United Arab Emirates
Background/Purpose: Thyroid dysfunction is common in rheumatoid arthritis (RA). Subclinical hypothyroidism is the first most common, followed by clinical hypothyroidism. Thyroid dysfunction in RA had…
Abstract Number: 1524 • 2016 ACR/ARHP Annual Meeting
Suppletion Therapy May be Warranted in RA Patients with Co-Existent Subclinical Hypothyroidism
Rabia Agca^1,2, Hennie Raterman², Suat Simsek³, Alexandre E. Voskuyl² and Mike T. Nurmohamed^1,4, ¹Rheumatology, Amsterdam Rheumatology and immunology Center, Location Reade, Amsterdam, Netherlands, ²Rheumatology, Amsterdam Rheumatology and immunology Center, Location VU University Medical Center, Amsterdam, Netherlands, ³Internal Medicine, Noodwest Ziekenhuisgroep, Location Alkmaar, Alkmaar, Netherlands, ⁴Rheumatology, Amsterdam Rheumatology and immunology Center, Location VU University Medical Center, Amsterdam, Netherlands, Amsterdam, Netherlands
Background/Purpose: Autoimmune thyroid disease often coexists with RA and has been associated with an elevated cardiovascular (CV) risk, especially in hypothyroid patients. However, the existing…
Abstract Number: 67 • 2012 ACR/ARHP Annual Meeting
Increased Prevalence of Hypothyroidism Preceding Rheumatoid Arthritis – an Epidemiological Study
Anne M. Kerola¹, Tuomo Nieminen², Markku J. Kauppi³, Hannu Kautiainen⁴, Kari Puolakka⁵, Lauri J. Virta⁶ and Tuomas Kerola³, ¹Medical School, University of Helsinki, Helsinki, Finland, ²Division of Cardiology, Helsinki University Central Hospital, Helsinki, Finland, ³Department of Internal Medicine, Päijät-Häme Central Hospital, Lahti, Finland, ⁴Unit of Primary Health Care, Kuopio University Hospital, Kuopio, Finland, ⁵Department of Medicine, South Karelia Central Hospital, Lappeenranta, Finland, ⁶Research Department, the Social Insurance Institution, Turku, Finland
Background/Purpose: Rheumatoid arthritis (RA) is associated with a wide set of comorbidities, including several autoimmune diseases such as autoimmune thyroiditis, which is a common cause…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].